Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 8/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093009 | 0.90 | TYK2 (0.42) | TYK2CYP19A1ALK | |
| SCHEMBL29686281 | 0.90 | TYK2 (0.42) | TYK2CYP19A1ALK | |
| SCHEMBL20073548 | 0.87 | CYP19A1 (0.39) | TYK2CYP19A1ALK | |
| SCHEMBL20150204 | 0.86 | CYP19A1 (0.43) | TYK2CYP19A1SMN1; SMN2 | |
| SCHEMBL20073547 | 0.85 | TYK2 (0.48) | TYK2CYP19A1L3MBTL1 | |
| SCHEMBL24498494 | 0.79 | HDAC1 (0.35) | TYK2 | |
| SCHEMBL29686947 | 0.79 | HDAC1 (0.35) | TYK2 | |
| SCHEMBL20093193 | 0.78 | TYK2 (0.49) | TYK2CYP19A1SLC6A9L3MBTL1 | |
| SCHEMBL20092137 | 0.77 | TYK2 (0.41) | TYK2HTR1DIKBKETBK1SLC6A9 | |
| SCHEMBL24498549 | 0.76 | CYP2C9 (0.35) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885HTR1D 4076/4885IKBKE 140/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885HTR1D 4076/4885IKBKE 140/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885HTR1D 4076/4885IKBKE 140/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885HTR1D 4076/4885IKBKE 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.